Edesa Biotech (EDSA) CEO Pardeep Nijhawan Receives 5,324 RSUs

What Happened Pardeep Nijhawan, CEO of Edesa Biotech (EDSA), was granted 5,324 restricted share units (RSUs) on 2026-08-03 that vested in full upon grant. The reported acquisition price was $0.00, so the RSUs converted to shares without cash payment. This was an award/grant (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-08-03; Form 4 filed 2026-08-04 (appears to be filed the next day).
• Shares acquired: 5,324 RSUs; acquisition price reported as $0.00 (total reported value $0).
• Shares owned after transaction: not specified in the filing.
• Footnotes of note:
  • F1: RSUs were granted pursuant to the Issuer's 2019 Equity Incentive Compensation Plan and vested in full upon grant.
  • F2: Certain entities (Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc., and 1968160 Ontario Inc.) are wholly-owned by the reporting person; he disclaims beneficial ownership except to the extent of his pecuniary interest.
  • F3: Reporting person is co-trustee of The New Nijhawan Family Trust 2015 and similarly disclaims beneficial ownership except to the extent of his pecuniary interest.

Context RSUs are compensation awards that convert to common shares when they vest; because these RSUs vested immediately, the reporting person became the holder of the resulting shares without paying cash. Such grants are common for executive compensation and do not, by themselves, indicate a buy/sell signal. The filing appears timely (filed the next business day).